| Outcome for patients with leukemia, multiple myeloma and lymphoma who relapse after high dose therapy and autologous stem cell support. | |
| | |
MedLine Citation:
|
PMID: 9049964 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Relapses after autologous transplantation are a serious clinical problem in patients with haematological diseases. The decision making for handling of such patients is difficult and the aim of this retrospective analysis of posttransplant relapses was 1) to obtain information of practical importance for the management of future relapses and 2) to evaluate the basis for clinical phase I-II trials of salvage therapy combined with biological modifiers. Included in the study were 283 patients with acute leukemia, multiple myeloma and malignant lymphoma who relapsed after autologous transplantations during a five year period from 1989 to 1994. Chemo- and radiotherapy was given to 229 patients after relapse or due to progressive disease and the response evaluated after 90 days. Fifty four patients (24%) obtained a complete remission and 44 patients (19%) partial responses. The overall median survival from relapse was 5 months. In the group given salvage treatment the median survival was 7 months and in the 54 patients who obtained remission the median survival was 15 months. So far 6 of 14 patients in continuous complete remission have a remission time after relapse longer than the time in remission after transplantation. Survival after relapse depended upon the time from transplantation to relapse, primary disease and if salvage therapy was given. In conclusion posttransplant relapses can be treated but the strategy has to be evaluated in future clinical trials. |
| | |
Authors:
|
H E Johnsen; B Björkstrand; K Carlson; A Gruber; A Blystad; A Fast; A M Boesen; M Björkholm; B Sallerfors; T Ruutu; J Carneskog; A Malm; C Geisler; M Lehtinen; H Schrøder; L Brinch; K Remes; U Tidefelt; C Heilmann; P Hörnsten; K Thorling; G Daugaard |
Related Documents
:
|
4077334 - Tuberculosis of the knee. 16241014 - Treatment results of methotrexate and folinic acid as primary chemotherapy for nonmetas... 3023204 - Poor prognosis metastatic gestational trophoblastic disease: experience with moderate d... 17536184 - Idiopathic organizing pneumonia: a relapsing disease. 19 years of experience in a hospi... 15006984 - Identical twins with primary pulmonary hypertension: beraprost vs epoprostenol. 19800604 - Increased slit immunoreactivity as a biomarker for recurrence in endometrial carcinoma. |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Leukemia & lymphoma Volume: 24 ISSN: 1042-8194 ISO Abbreviation: Leuk. Lymphoma Publication Date: 1996 Dec |
Date Detail:
|
Created Date: 1997-08-19 Completed Date: 1997-08-19 Revised Date: 2004-11-17 |
Medline Journal Info:
|
Nlm Unique ID: 9007422 Medline TA: Leuk Lymphoma Country: SWITZERLAND |
Other Details:
|
Languages: eng Pagination: 81-91 Citation Subset: IM |
Affiliation:
|
Dept. of Haematology, Herlev Hospital, University of Copenhagen, Denmark. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Antineoplastic Agents / therapeutic use* Child Child, Preschool Combined Modality Therapy Dose-Response Relationship, Drug Dose-Response Relationship, Radiation Female Hematopoietic Stem Cell Transplantation* Humans Infant Leukemia / mortality, therapy* Lymphoma / mortality, therapy* Male Middle Aged Multiple Myeloma / mortality, therapy* Recurrence Remission Induction / methods Retrospective Studies Salvage Therapy / methods Transplantation, Autologous Treatment Outcome |
| Chemical | |
Reg. No./Substance:
|
0/Antineoplastic Agents |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: The highest leukaemia-free survival after allogeneic bone marrow transplantation is seen in patients...
Next Document: Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurr...